Table 3 Comparison of baseline patients’ medications between those with perforation and those without perforation by univariate analysis
From: Evaluation of risk factors for perforated peptic ulcer
Case subjects (those with perforation) | Control subjects (those without perforation) | p-value | |
|---|---|---|---|
n = 136 | n = 272 | ||
Medications | |||
Antiplatelet, n (%) | 0.78 | ||
None, n (%) | 127 (93.4) | 256 (94.1) | |
Aspirin, n (%) | 6 (4.4) | 11 (4.0) | |
Clopidogrel, n (%) | 0 (0.0) | 1 (0.4) | |
Limaprost alfadex, n (%) | 0 (0.0) | 1 (0.4) | |
Dual Antiplatelet Therapy, n (%) | 3 (2.2) | 3 (1.1) | |
Anticoagulant, n (%) | 7 (5.1) | 9 (3.3) | 0.42 |
NSAIDs daily, n (%) | 15 (11.0) | 13 (4.8) | 0.02 |
NSAIDs rescue, n (%) | 11 (8.1) | 16 (5.9) | 0.40 |
Proton pump inhibitor, n (%) | 10 (7.4) | 21 (7.7) | 1.00 |
H2 blocker, n (%) | 1 (0.7) | 10 (3.7) | 0.11 |
Bisphosphonate, n (%) | 4 (2.9) | 3 (1.1) | 0.23 |
Spironolactone, n (%) | 1 (0.7) | 7 (2.6) | 0.28 |
Steroid, n (%) | 5 (3.7) | 8 (2.9) | 0.77 |